Comment Letters

نویسنده

  • C. P. Panayiotopoulos
چکیده

To the Editor: Inspired by C. P. Panayiotopoulos’ letter to you and F. Andermann’s response about epilepsy of Kozhevnikov (Epilepsia 2002:43:948–9), I would like to defend the famous name of John Hughlings Jackson because it seems to me his importance is underestimated. His priority in study of convulsions in brain connected to motor cortex is obvious. He was the first to use epilepsy as an instrument for scientific understanding of the brain structural–functional organization (1,2). The International Classification of Epilepsies, Epileptic Syndromes, and Related Seizure Disorders, 1989 (3), as well as a Proposed Diagnostic Scheme for People with Epileptic Seizures and with Epilepsy (4) does not include Jackson’s name, although this seizure type is correctly called a “jacksonian seizure” by neurologists all over the world. This fact cannot be completely explained by the tendency to replace eponymic terminology with a neurobiologic term, because the classification refers to epilepsia partialis continua of Kozhevnikov. The axis, “An example of a classification of epilepsy syndromes” contains different forms of epilepsies and epileptic syndromes, with authors named for early-onset benign childhood epilepsy (Panayiotopoulos), late-onset benign childhood epilepsy (Gastaut type) or simply Lennox–Gastaut syndrome, Landau–Kleffner syndrome, and so on. This axis distinguishes “neocortical epilepsies” including that described later than Jackson’s form, Rasmussen syndrome, but it is very strange that jacksonian epilepsy also is not here. I think it would be justified to add into the item “Focal motor seizures” of the axis 2, “Epileptic seizure types . . .”, jacksonian seizures, and into the item “Neocortical epilepsies of the axis 3,” “Epilepsy syndromes and related conditions,” to include Epilepsy of projecting motor cortex (jacksonian epilepsy).

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”

The above titled paper examined the Food and Drug Administration’s (FDA’s) warning letters and notice of violations (NOV) over a 10-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning, the fair balance of risk and benefit information. As opposed to another analysis in 2026 about th...

متن کامل

Considering the Future of Pharmaceutical Promotions in Social Media; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”

This commentary explores the implications of increased social media marketing by drug manufacturers, based on findings in Hyosun Kim’s article of the major themes in recent Food and Drug Administration (FDA) warning letters and notices of violation regarding online direct-to-consumer promotions of pharmaceuticals. Kim’s rigorous analysis of FDA letters over a 10-year span highlights a relative ...

متن کامل

The Conundrum of Online Prescription Drug Promotion; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”

This commentary discusses pertinent issues from Hyosun Kim’s paper on online prescription drug promotion. The study is well-designed and the findings highlight some of the consequences of the Food and Drug Administration’s (FDA’s) decision to deregulate online advertising of prescription drugs. While Kim’s findings confirm some of the early concerns, they also provide a perspective of implement...

متن کامل

Future Challenges and Opportunities in Online Prescription Drug Promotion Research; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”

Despite increased availability of online promotional tools for prescription drug marketers, evidence on online prescription drug promotion is far from settled or conclusive. We highlight ways in which online prescription drug promotion is similar to conventional broadcast and print advertising and ways in which it differs. We also highlight five key areas for future research: branded drug websi...

متن کامل

Digital Direct-to-Consumer Advertising: A Perfect Storm of Rapid Evolution and Stagnant Regulation; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”

The adoption and use of digital forms of direct-to-consumer advertising (also known as “eDTCA”) is on the rise. At the same time, the universe of eDTCA is expanding, as technology on Internet-based platforms continues to evolve, from static websites, to social media, and nearly ubiquitous use of mobile devices. However, little is known about how this unique form of pharmaceutical marketing impa...

متن کامل

The Tip of the Iceberg of Misleading Online Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”

Kim’s overview of Food and Drug Administration (FDA) regulatory actions from 2005 to 2014 is a comprehensive analysis of the US regulatory experience with online direct-to-consumer advertising (DTCA) of prescription medicines. This experience is of relevance internationally as online DTCA reaches the English-speaking public globally, despite the illegality of DTCA in most countries. The most co...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2003